KAMUYU AYDINLATMA PLATFORMU

MEDİTERA TIBBİ MALZEME SANAYİ VE TİCARET A.Ş.
Financial Report
Consolidated
2026 - 2. 3 Monthly Notification

General Information About Financial Statements
Financial Report

Independet Audit Comment

Independent Audit Company	ARTI DEĞER ULUSLARARASI BAĞIMSIZ DENETİM VE YMM A.Ş.
Audit Type	Limited
Audit Result	Positive

MEDİTERA TIBBİ MALZEME SANAYİ VE TİCARET ANONİM ŞİRKETİ

01 OCAK – 30 HAZİRAN 2026 HESAP DÖNEMİNE AİT

KONSOLİDE FİNANSAL TABLOLARI HAKKINDA

SINIRLI DENETİM RAPORU

Meditera Tıbbi Malzeme Sanayi ve Ticaret Anonim Şirketi

Genel Kurulu'na

Giriş

Meditera Tıbbi Malzeme Sanayi ve Ticaret Anonim Şirketi ("Grup") 30 Haziran 2026 tarihli ilişikteki konsolide finansal durum tablosunun ve aynı tarihte sona eren altı aylık döneme ait konsolide kar veya zarar tablosunun, konsolide kar veya zarar ve diğer kapsamlı gelir tablosunun, konsolide özkaynak değişim tablosunun ve konsolide nakit akış tablosu ile önemli muhasebe politikalarının özetinin ve diğer açıklayıcı dipnotlarının sınırlı denetimini yürütmüş bulunuyoruz. Grup yönetimi, söz konusu ara dönem özet finansal bilgilerin Kamu Gözetimi Muhasebe ve Denetim Standartları Kurumu ("KGK") tarafından yayımlanan Türkiye Muhasebe Standardı 34 "Ara Dönem Finansal Raporlama" Standardına ("TMS 34") uygun olarak hazırlanmasından ve sunumundan sorumludur. Sorumluluğumuz, yaptığımız sınırlı denetime dayanarak söz konusu ara dönem özet finansal bilgilere ilişkin bir sonuç bildirmektir.

Sınırlı Denetimin Kapsamı

Yaptığımız sınırlı denetim Sınırlı Bağımsız Denetim Standardı ("SBDS") 2410 "Ara Dönem Finansal Bilgilerin, İşletmenin Yıllık Finansal Tablolarının Bağımsız Denetimini Yürüten Denetçi Tarafından Sınırlı Bağımsız Denetimi" ne uygun olarak yürütülmüştür. Ara dönem finansal bilgilere ilişkin sınırlı denetim, başta finans ve muhasebe konularından sorumlu kişiler olmak üzere ilgili kişilerin sorgulanması ve analitik prosedürler ile diğer sınırlı denetim prosedürlerinin uygulanmasından oluşur. Ara dönem finansal bilgilerin sınırlı denetiminin kapsamı; Bağımsız Denetim Standartları'na uygun olarak yapılan ve amacı finansal tablolar hakkında bir görüş bildirmek olan bağımsız denetimin kapsamına kıyasla önemli ölçüde dardır. Sonuç olarak ara dönem finansal bilgilerin sınırlı denetimi, denetim şirketinin, bir bağımsız denetimde belirlenebilecek tüm önemli hususlara vâkıf olabileceğine ilişkin bir güvence sağlamamaktadır. Bu sebeple, bir bağımsız denetim görüşü bildirmemekteyiz.

Sonuç

Meditera Tıbbi Malzeme Sanayi ve Ticaret Anonim Şirketi ("Grup") 30 Haziran 2026 tarihli ilişikteki özet finansal durum tablosunun ve aynı tarihte sona eren altı aylık ara hesap dönemine ait özet kar veya zarar tablosunun, diğer kapsamlı gelir tablosunun, özkaynak değişim tablosunun ve nakit akış tablosunun sınırlı denetimini yürütmüş bulunuyoruz.

Sınırlı denetimimize göre ilişikteki ara dönem özet finansal bilgilerin, tüm önemli yönleriyle, TMS 34 "Ara Dönem Finansal Raporlama" Standard'ına uygun olarak hazırlanmadığı kanaatine varmamıza sebep olacak herhangi bir husus dikkatimizi çekmemiştir.

Bu bağımsız denetimi yürütüp sonuçlandıran sorumlu denetçi Süleyman Taf'tır.

İstanbul, 14 Ağustos 2026

Artı Değer Uluslararası Bağımsız Denetim ve YMM A.Ş.

Mimar Sinan Mah. Mimar Sinan Cad. Birlik İş Merkezi No:15 Kat:2 D:6 Çekmeköy/İSTANBUL

Süleyman Taf, YMM

Sorumlu Denetçi,

Statement of Financial Position (Balance Sheet)

Presentation Currency	TL
Nature of Financial Statements	Consolidated

	Footnote Reference	Current Period 30.06.2026	Previous Period 31.12.2025
Statement of Financial Position (Balance Sheet)			
Assets [abstract]			
CURRENT ASSETS			
Cash and cash equivalents	52	472.639.248	372.066.685
Financial Investments	44	11.618.407	82.972.367
Trade Receivables	7	706.524.380	896.062.727
Trade Receivables Due From Related Parties	6	6.729.102	2.814.456
Trade Receivables Due From Unrelated Parties	7	699.795.278	893.248.271
Other Receivables	8	18.086.805	47.560.628
Other Receivables Due From Unrelated Parties	8	18.086.805	47.560.628
Inventories	9	664.724.092	648.200.440
Prepayments	11	84.934.091	81.400.443
Prepayments to Related Parties	6	0	4.197.451
Prepayments to Unrelated Parties	11	84.934.091	77.202.992
Other current assets	27	33.703.572	16.565.696
SUB-TOTAL		**1.992.230.595**	**2.144.828.986**
Total current assets		**1.992.230.595**	**2.144.828.986**
NON-CURRENT ASSETS			
Other Receivables	8	69.574	97.566
Other Receivables Due From Unrelated Parties	8	69.574	97.566
Investments accounted for using equity method	4	14.647.858	17.152.323
Investment property	12	82.479.038	82.479.038
Property, plant and equipment	13	1.795.546.228	1.835.584.739
Right of Use Assets	19	49.596.601	55.108.802
Intangible assets and goodwill	16	89.062.159	92.949.215
Goodwill	17	75.998.098	75.998.098
Other intangible assets	16	13.064.061	16.951.117
Total non-current assets		**2.031.401.458**	**2.083.371.683**
Total assets		**4.023.632.053**	**4.228.200.669**
LIABILITIES AND EQUITY			
CURRENT LIABILITIES			
Current Portion of Non-current Borrowings	44	21.178.156	29.526.071
Current Portion of Non-current Borrowings from Related Parties	6	7.293.968	8.146.430
Current Portion of Non-current Borrowings from Unrelated Parties	44	13.884.188	21.379.641
Trade Payables	7	387.087.999	483.104.553
Trade Payables to Related Parties	6	1.058.922	40.847.382
Trade Payables to Unrelated Parties	7	386.029.077	442.257.171
Employee Benefit Obligations	26	45.612.232	51.175.768
Other Payables	8	14.065.452	20.491.749
Other Payables to Related Parties	6	0	2.131.594
Other Payables to Unrelated Parties	8	14.065.452	18.360.155
Deferred Income Other Than Contract Liabilities	11	25.015.149	24.357.411
Deferred Income Other Than Contract Liabilities from Unrelated Parties	11	25.015.149	24.357.411
Current tax liabilities, current	38	1.654.881	977.478
Current provisions	24	35.411.001	28.071.268
Current provisions for employee benefits	24	31.811.377	23.302.165
Other current provisions	24	3.599.624	4.769.103
SUB-TOTAL		**530.024.870**	**637.704.298**
Total current liabilities		**530.024.870**	**637.704.298**
NON-CURRENT LIABILITIES			
Long Term Borrowings	44	6.727.261	16.307.521
Long Term Borrowings From Related Parties	6	4.814.335	7.155.235
Long Term Borrowings From Unrelated Parties	44	1.912.926	9.152.286
Non-current provisions	24	46.405.777	48.002.878
Non-current provisions for employee benefits	24	46.405.777	48.002.878
Deferred Tax Liabilities	38	52.207.336	76.490.419
Total non-current liabilities		**105.340.374**	**140.800.818**
Total liabilities		**635.365.244**	**778.505.116**

EQUITY			
Equity attributable to owners of parent		3.359.521.919	3.421.793.234
Issued capital	28	119.000.000	119.000.000
Inflation Adjustments on Capital	28	943.342.689	943.342.689
Treasury Shares (-)	28	-25.588.267	-26.435.900
Share Premium (Discount)	28	824.081.213	824.081.213
Other Accumulated Comprehensive Income (Loss) that will not be Reclassified in Profit or Loss	28	385.347.626	385.347.626
Gains (Losses) on Revaluation and Remeasurement	28	385.347.626	385.347.626
Increases (Decreases) on Revaluation of Property, Plant and Equipment	28	385.990.263	385.990.263
Gains (Losses) on Remeasurements of Defined Benefit Plans	28	-642.637	-642.637
Other Accumulated Comprehensive Income (Loss) that will be Reclassified in Profit or Loss	28	154.688.070	139.615.161
Exchange Differences on Translation	28	154.688.070	139.615.161
Restricted Reserves Appropriated From Profits	28	276.850.684	276.850.684
Prior Years' Profits or Losses	28	759.991.761	770.910.262
Current Period Net Profit Or Loss	28	-78.191.857	-10.918.501
Non-controlling interests		28.744.890	27.902.319
Total equity		**3.388.266.809**	**3.449.695.553**
Total Liabilities and Equity		**4.023.632.053**	**4.228.200.669**

Statement of Profit or Loss and Other Comprehensive Income

Presentation Currency	TL
Nature of Financial Statements	Consolidated

	Footnote Reference	Current Period 01.01.2026 - 30.06.2026	Previous Period 01.01.2025 - 30.06.2025	Current Period 3 Months 01.04.2026 - 30.06.2026	Previous Period 3 Months 01.04.2025 - 30.06.2025
Statement of Profit or Loss and Other Comprehensive Income					
PROFIT (LOSS)					
Revenue	29	1.360.001.932	1.659.097.593	668.467.041	818.330.504
Cost of sales	29	-901.608.971	-1.126.247.610	-439.238.025	-549.330.883
GROSS PROFIT (LOSS) FROM COMMERCIAL OPERATIONS		458.392.961	532.849.983	229.229.016	268.999.621
GROSS PROFIT (LOSS)		458.392.961	532.849.983	229.229.016	268.999.621
General Administrative Expenses	31	-222.802.131	-219.124.474	-96.817.532	-101.433.399
Marketing Expenses	31	-178.003.666	-195.911.842	-89.104.724	-96.268.137
Research and development expense	31	-17.823.858	-20.925.042	-8.406.352	-10.869.538
Other Income from Operating Activities	32	57.574.486	134.574.279	11.502.793	79.983.518
Other Expenses from Operating Activities	32	-70.787.352	-133.332.996	-30.644.975	-71.143.943
PROFIT (LOSS) FROM OPERATING ACTIVITIES		26.550.440	98.129.908	15.758.226	69.268.122
Investment Activity Income	33	10.822.481	4.442.712	8.758.433	4.442.712
Investment Activity Expenses	33	-192.413	0	-57.684	1.098.564
Impairment gain and reversal of impairment loss (impairment loss) determined in accordance with IFRS 9	33	-248.095	-739.174	-521.022	333.188
Share of Profit (Loss) from Investments Accounted for Using Equity Method	33	-2.504.465	-21.244.223	-1.007.340	-18.550.552
PROFIT (LOSS) BEFORE FINANCING INCOME (EXPENSE)		34.427.948	80.589.223	22.930.613	56.592.034
Finance income	35	63.540.078	92.405.244	29.452.292	42.071.146
Finance costs	35	-6.781.354	-15.420.379	-3.157.985	-6.526.416
Gains (losses) on net monetary position	50	-184.217.108	-204.793.839	-72.068.986	-84.727.107
PROFIT (LOSS) FROM CONTINUING OPERATIONS, BEFORE TAX		-93.030.436	-47.219.751	-22.844.066	7.409.657
Tax (Expense) Income, Continuing Operations		15.681.150	-81.453.669	2.613.400	-35.546.940
Current Period Tax (Expense) Income	38	-8.601.933	-10.514.769	-5.820.502	-8.576.973
Deferred Tax (Expense) Income	38	24.283.083	-70.938.900	8.433.902	-26.969.967
PROFIT (LOSS) FROM CONTINUING OPERATIONS		-77.349.286	-128.673.420	-20.230.666	-28.137.283
PROFIT (LOSS)		-77.349.286	-128.673.420	-20.230.666	-28.137.283
Profit (loss), attributable to [abstract]					
Non-controlling Interests	39	842.571	-4.809.837	-862.431	-2.298.458
Owners of Parent	39	-78.191.857	-123.863.583	-19.368.235	-25.838.825
Earnings per share [abstract]					
Earnings per share [line items]					
Basic earnings per share					
Diluted Earnings Per Share					
OTHER COMPREHENSIVE INCOME					
Other Comprehensive Income that will not be Reclassified to Profit or Loss		0	0	0	0
Other Comprehensive Income That Will Be Reclassified to Profit or Loss		15.072.909	44.163.046	14.223.183	13.499.410
Change in Value of Foreign Currency Basis Spreads	36	15.072.909	44.163.046	14.223.183	13.499.410
Gains (Losses) on Change in Value of Foreign Currency Basis Spreads	36	15.072.909	44.163.046	14.223.183	13.499.410
OTHER COMPREHENSIVE INCOME (LOSS)		**15.072.909**	**44.163.046**	**14.223.183**	**13.499.410**
TOTAL COMPREHENSIVE INCOME (LOSS)		**-62.276.377**	**-84.510.374**	**-6.007.483**	**-14.637.873**
Total Comprehensive Income Attributable to					
Non-controlling Interests		842.571	-4.809.838	-862.431	-2.298.458
Owners of Parent		-63.118.948	-79.700.536	-5.145.052	-12.339.415

Statement of cash flows (Indirect Method)

Presentation Currency	TL
Nature of Financial Statements	Consolidated

	Footnote Reference	Current Period 01.01.2026 - 30.06.2026	Previous Period 01.01.2025 - 30.06.2025
Statement of cash flows (Indirect Method)			
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES		**275.579.570**	**170.576.790**
Profit (Loss)		-77.349.286	-128.673.420
Profit (Loss) from Continuing Operations	39	-77.349.286	-128.673.420
Adjustments to Reconcile Profit (Loss)		**50.089.698**	**206.442.509**
Adjustments for depreciation and amortisation expense	13,16,19	104.766.551	97.648.696
Adjustments for Impairment Loss (Reversal of Impairment Loss)		1.021.266	721.492
Adjustments for Impairement Loss (Reversal of Impairment Loss) of Receivables	7	56.667	-168.629
Adjustments for Impairment Loss (Reversal of Impairment Loss) of Inventories	9	964.599	890.121
Adjustments for provisions	24	1.420.772	-606.620
Adjustments for (Reversal of) Provisions Related with Employee Benefits		3.309.501	532.411
Adjustments for (Reversal of) Other Provisions		-1.888.729	-1.139.031
Adjustments for Interest (Income) Expenses	32,35	-27.138.429	-24.075.296
Adjustments for Interest Income		-31.013.778	-30.295.921
Adjustments for interest expense		6.025.803	12.692.858
Deferred Financial Expense from Credit Purchases		9.980.164	18.752.805
Unearned Financial Income from Credit Sales		-12.130.618	-25.225.038
Adjustments for unrealised foreign exchange losses (gains)		-5.983.087	31.139.184
Adjustments for Undistributed Profits of Investments Accounted for Using Equity Method		2.504.465	21.244.223
Adjustments for undistributed profits of associates		2.504.465	21.244.223
Adjustments for Tax (Income) Expenses		-15.681.150	81.453.669
Adjustments for losses (gains) on disposal of non-current assets	33	-10.820.690	-4.442.712
Adjustments for Losses (Gains) Arised From Sale of Tangible Assets		-10.820.690	-4.442.712
Adjustments Related to Gain and Losses on Net Monetary Position		0	3.359.873
Changes in Working Capital		**309.596.874**	**129.640.699**
Decrease (Increase) in Financial Investments	44	83.867.399	117.900.393
Adjustments for decrease (increase) in trade accounts receivable		314.640.802	29.648.404
Decrease (Increase) in Trade Accounts Receivables from Related Parties		-3.490.185	-4.374.737
Decrease (Increase) in Trade Accounts Receivables from Unrelated Parties		318.130.987	34.023.141
Adjustments for Decrease (Increase) in Other Receivables Related with Operations		36.689.364	-4.870.437
Decrease (Increase) in Other Unrelated Party Receivables Related with Operations	7	36.689.364	-4.870.437
Adjustments for decrease (increase) in inventories		65.711.271	84.518.814
Decrease (Increase) in Prepaid Expenses	11	5.681.483	5.679.197
Adjustments for increase (decrease) in trade accounts payable	6,7	-156.745.126	-133.050.200
Increase (Decrease) in Trade Accounts Payables to Related Parties	6	-45.948.839	-3.946.869
Increase (Decrease) in Trade Accounts Payables to Unrelated Parties	7	-110.796.287	-129.103.331
Increase (Decrease) in Employee Benefit Liabilities	26	-13.281.586	-2.104.459
Adjustments for increase (decrease) in other operating payables	8,6	-9.516.752	-2.537.081
Increase (Decrease) in Other Operating Payables to Related Parties	6	-2.453.070	0
Increase (Decrease) in Other Operating Payables to Unrelated Parties	8	-7.063.682	-2.537.081
Increase (Decrease) in Deferred Income Other Than Contract Liabilities		-3.015.184	18.213.785
Other Adjustments for Other Increase (Decrease) in Working Capital		-14.434.797	16.242.283
Decrease (Increase) in Other Assets Related with Operations	27	-14.434.797	16.242.283
Cash Flows from (used in) Operations		**282.337.286**	**207.409.788**

Payments Related with Provisions for Employee Benefits		-7.151.227	-5.356.318
Income taxes refund (paid)		-20.916.196	28.821.238
Inflation Effect On Operating Activities		21.309.707	-60.297.918
CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES		**240.830.662**	**225.767.462**
Proceeds from sales of property, plant, equipment and intangible assets		19.053.126	4.322.563
Proceeds from sales of property, plant and equipment		19.053.126	4.322.563
Purchase of Property, Plant, Equipment and Intangible Assets		-67.086.293	-38.364.051
Purchase of property, plant and equipment	13	-63.178.219	-38.031.496
Purchase of intangible assets	16	-3.908.074	-332.555
Inflation Effect On Investing Activities		288.863.829	259.808.950
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES		**-105.478.038**	**-127.515.183**
Payments to Acquire Entity's Shares or Other Equity Instruments		0	-12.924.074
Payments to Acquire Entity's Shares		0	-12.924.074
Cash Inflows from Sale of Acquired Entity's Shares or Other Equity Instruments		907.826	0
Cash Inflows from Sale of Acquired Entity's Shares		907.826	0
Repayments of borrowings		-4.500.000	-17.892.537
Loan Repayments		-4.500.000	-17.892.537
Payments of Lease Liabilities		-3.755.350	0
Interest paid	32,35	-6.025.803	-12.692.858
Interest Received	32,35	31.013.778	30.295.921
Inflation Effect On Financing Activities		-123.118.489	-114.301.635
INFLATION EFFECT		-366.472.696	-351.692.209
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS BEFORE EFFECT OF EXCHANGE RATE CHANGES		44.459.498	-82.863.140
Net increase (decrease) in cash and cash equivalents		44.459.498	-82.863.140
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	52	**372.066.685**	**465.913.220**
INFLATION EFFECT ON CASH AND CASH EQUIVALENTS		56.113.065	66.583.894
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	52	**472.639.248**	**449.633.974**

Statement of changes in equity [abstract]

Presentation Currency	TL
Nature of Financial Statements	Consolidated

		Footnote Reference	Equity														
			Equity attributable to owners of parent [member]													Non-controlling interests [member]	
			Issued Capital	Inflation Adjustments on Capital	Treasury Shares	Share premiums or discounts	Other Accumulated Comprehensive Income That Will Not Be Reclassified In Profit Or Loss		Other Accumulated Comprehensive Income That Will Be Reclassified In Profit Or Loss			Restricted Reserves Appropriated From Profits [member]	Retained Earnings				
							Gains/Losses on Revaluation and Remeasurement [member]		Exchange Differences on Translation	Reserve Of Gains or Losses on Hedge	Gains (Losses) on Revaluation and Reclassification		Prior Years' Profits or Losses	Net Profit or Loss			
							Increases (Decreases) on Revaluation of Property, Plant and Equipment	Gains (Losses) on Remeasurements of Defined Benefit Plans									
Previous Period 01.01.2025 - 30.06.2025	**Statement of changes in equity [abstract]**																
	Statement of changes in equity [line items]																
	Equity at beginning of period		**119.000.000**	**943.342.689**	**-13.599.533**	**824.081.213**	**379.658.722**	**-2.221.006**	**91.132.992**			**276.850.684**	**705.839.956**	**113.183.970**	**3.437.269.687**	**7.727.676**	**3.444.997.363**
	Adjustments Related to Accounting Policy Changes																
	Adjustments Related to Required Changes in Accounting Policies																
	Adjustments Related to Voluntary Changes in Accounting Policies																
	Adjustments Related to Errors																
	Other Restatements																
	Restated Balances																
	Transfers	28											113.183.970	-113.183.970			
	Total Comprehensive Income (Loss)	28							44.163.046					-123.863.583	-79.700.536	-4.809.837	-84.510.373
	Profit (loss)	28												-123.863.583	-123.863.583	-4.809.837	-128.673.420
	Other Comprehensive Income (Loss)	28							44.163.046						44.163.046		44.163.046
	Issue of equity																
	Capital Decrease																
	Capital Advance																
	Effect of Merger or Liquidation or Division																
	Effects of Business Combinations Under Common Control																
	Advance Dividend Payments																
	Dividends Paid																
	Decrease through Other Distributions to Owners																
	Increase (Decrease) through Treasury Share Transactions	28			-12.610.892										-12.610.892		-12.610.892
	Increase (Decrease) through Share-Based Payment Transactions	28				-556.409									-556.409		-556.409
	Acquisition or Disposal of a Subsidiary																
	Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity																
	Transactions with noncontrolling shareholders																
	Increase through Other Contributions by Owners																
	Amount Removed from Reserve of Cash Flow Hedges and Included in Initial Cost or Other Carrying Amount of Non-Financial Asset (Liability) or Firm Commitment for which Fair Value Hedge Accounting is Applied																
	Amount Removed from Reserve of Change in Value of Time Value of Options and Included in Initial Cost or Other Carrying Amount of Non-Financial Asset (Liability) or Firm Commitment for which Fair Value Hedge Accounting is Applied																
	Amount Removed from Reserve of Change in Value of Forward Elements of Forward Contracts and Included in Initial Cost or Other Carrying Amount of Non-Financial Asset (Liability) or Firm Commitment for which Fair Value Hedge Accounting is Applied																
	Amount Removed from Reserve of Change in Value of Foreign Currency Basis Spreads and Included in Initial Cost or Other Carrying Amount of Non-Financial Asset (Liability) or Firm Commitment for which fair Value Hedge Accounting is Applied																
	Increase (decrease) through other changes, equity																
	Equity at end of period		**119.000.000**	**943.342.689**	**-26.210.424**	**823.524.804**	**379.658.722**	**-2.221.006**	**135.296.038**			**276.850.684**	**819.023.926**	**-123.863.583**	**3.344.401.850**	**2.917.838**	**3.347.319.688**
	Statement of changes in equity [abstract]																
	Statement of changes in equity [line items]																
	Equity at beginning of period		**119.000.000**	**943.342.689**	**-26.435.900**	**824.081.213**	**385.990.263**	**-642.637**	**139.615.161**			**276.850.684**	**770.910.262**	**-10.918.501**	**3.421.793.234**	**27.902.319**	**3.449.695.553**
	Adjustments Related to Accounting Policy Changes																
	Adjustments Related to Required Changes in Accounting Policies																
	Adjustments Related to Voluntary Changes in Accounting Policies																
	Adjustments Related to Errors																
	Other Restatements																
	Restated Balances																
	Transfers	28											-10.918.501	10.918.501			
	Total Comprehensive Income (Loss)	28												-78.191.857	-63.118.948	842.571	-62.276.377
	Profit (loss)	28							15.072.909					-78.191.857	-78.191.857	842.571	-77.349.286
	Other Comprehensive Income (Loss)	28													15.072.909		15.072.909
	Issue of equity																
	Capital Decrease																
	Capital Advance																
	Effect of Merger or Liquidation or Division																
	Effects of Business Combinations Under Common Control																
	Advance Dividend Payments																
	Dividends Paid																

Current Period 01.01.2026 - 30.06.2026																	
	Decrease through Other Distributions to Owners																
	Increase (Decrease) through Treasury Share Transactions	28			847.633										847.633		847.633
	Increase (Decrease) through Share-Based Payment Transactions																
	Acquisition or Disposal of a Subsidiary																
	Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity																
	Transactions with noncontrolling shareholders																
	Increase through Other Contributions by Owners																
	Amount Removed from Reserve of Cash Flow Hedges and Included in Initial Cost or Other Carrying Amount of Non-Financial Asset (Liability) or Firm Commitment for which Fair Value Hedge Accounting is Applied																
	Amount Removed from Reserve of Change in Value of Time Value of Options and Included in Initial Cost or Other Carrying Amount of Non-Financial Asset (Liability) or Firm Commitment for which Fair Value Hedge Accounting is Applied																
	Amount Removed from Reserve of Change in Value of Forward Elements of Forward Contracts and Included in Initial Cost or Other Carrying Amount of Non-Financial Asset (Liability) or Firm Commitment for which Fair Value Hedge Accounting is Applied																
	Amount Removed from Reserve of Change in Value of Foreign Currency Basis Spreads and Included in Initial Cost or Other Carrying Amount of Non-Financial Asset (Liability) or Firm Commitment for which fair Value Hedge Accounting is Applied																
	Increase (decrease) through other changes, equity																
	Equity at end of period		**119.000.000**	**943.342.689**	**-25.588.267**	**824.081.213**	**385.990.263**	**-642.637**	**154.688.070**			**276.850.684**	**759.991.761**	**-78.191.857**	**3.359.521.919**	**28.744.890**	**3.388.266.809**